The stock of Eagle Pharmaceuticals Inc (EGRX) has seen a -37.11% decrease in the past week, with a -47.64% drop in the past month, and a -55.64% decrease in the past quarter. The volatility ratio for the week is 7.42%, and the volatility levels for the past 30 days are at 9.89% for EGRX. The simple moving average for the last 20 days is -39.74% for EGRX stock, with a simple moving average of -49.86% for the last 200 days.
Is It Worth Investing in Eagle Pharmaceuticals Inc (NASDAQ: EGRX) Right Now?
The 36-month beta value for EGRX is also noteworthy at 0.51. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 1 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EGRX is 11.43M, and at present, short sellers hold a 3.07% of that float. The average trading volume of EGRX on October 02, 2024 was 105.08K shares.
EGRX) stock’s latest price update
The stock price of Eagle Pharmaceuticals Inc (NASDAQ: EGRX) has plunged by -31.46 when compared to previous closing price of 3.56, but the company has seen a -37.11% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-27 that WOODCLIFF LAKE, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on August 21, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that pursuant to Nasdaq Listing Rule 5810(d)(2), the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) serves as an additional and separate basis for delisting.
Analysts’ Opinion of EGRX
Many brokerage firms have already submitted their reports for EGRX stocks, with Piper Sandler repeating the rating for EGRX by listing it as a “Underweight.” The predicted price for EGRX in the upcoming period, according to Piper Sandler is $17 based on the research report published on August 10, 2023 of the previous year 2023.
Piper Sandler, on the other hand, stated in their research note that they expect to see EGRX reach a price target of $17, previously predicting the price at $26. The rating they have provided for EGRX stocks is “Underweight” according to the report published on August 09th, 2023.
RBC Capital Mkts gave a rating of “Outperform” to EGRX, setting the target price at $52 in the report published on April 07th of the previous year.
EGRX Trading at -44.94% from the 50-Day Moving Average
After a stumble in the market that brought EGRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.45% of loss for the given period.
Volatility was left at 9.89%, however, over the last 30 days, the volatility rate increased by 7.42%, as shares sank -44.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -55.91% lower at present.
During the last 5 trading sessions, EGRX fell by -34.43%, which changed the moving average for the period of 200-days by -48.39% in comparison to the 20-day moving average, which settled at $3.95. In addition, Eagle Pharmaceuticals Inc saw -53.35% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EGRX starting from Tarriff Scott, who sale 10,925 shares at the price of $13.82 back on Nov 01 ’23. After this action, Tarriff Scott now owns 556,141 shares of Eagle Pharmaceuticals Inc, valued at $150,984 using the latest closing price.
Tarriff Scott, the CEO of Eagle Pharmaceuticals Inc, sale 10,694 shares at $13.87 during a trade that took place back on Nov 02 ’23, which means that Tarriff Scott is holding 545,447 shares at $148,326 based on the most recent closing price.
Stock Fundamentals for EGRX
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.7 for the gross margin
The net margin for Eagle Pharmaceuticals Inc stands at 0.11. The total capital return value is set at 0.18.
Based on Eagle Pharmaceuticals Inc (EGRX), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at 0.49. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is 13.21.
Currently, EBITDA for the company is 65.48 million with net debt to EBITDA at 0.11. When we switch over and look at the enterprise to sales, we see a ratio of 0.12. The receivables turnover for the company is 4.37for trailing twelve months and the total asset turnover is 0.78.
Conclusion
In summary, Eagle Pharmaceuticals Inc (EGRX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
